adminSanofi (SAN:CA) Discusses Year-End Late-Stage Pipeline Review With Focus on Clinical and Regulatory Developments December 16, 2025 11:15 AM EST
Company Participants
Thomas Larsen – Head of Investor Relations
Houman Ashrafian – Executive VP & Head of Research Development
Jean-Francois Toussaint – Global Head of Research & Development Vaccines – Sanofi Pasteur
Conference Call Participants
Peter Verdult – BNP Paribas, Research Division
Luisa Hector – Joh. Berenberg, Gossler & Co. KG, Research Division
Richard Vosser – JPMorgan Chase & Co, Research Division
Sachin Jain – BofA Securities, Research Division
Simon Baker – Rothschild & Co Redburn, Research Division
James Quigley – Goldman Sachs Group, Inc., Research Division
Sarita Kapila – Morgan Stanley, Research Division
Graham Glyn Parry – Citigroup Inc., Research Division
Christopher LoBianco – TD Cowen, Research Division
Emmanuel Papadakis – Deutsche Bank AG, Research Division
Presentation
Thomas Larsen
Head of Investor Relations
Good afternoon and good morning, depending on where you are, and welcome to the Sanofi’s first year-end late-stage pipeline review. I’m Thomas Kudsk Larsen from the Investor Relations team and I’m pleased to see so many people on the call today.
Before we get started, I want to thank Alizé in the IR team for leading the work on today’s call. I also want to remind everyone that our focus is on the clinical and regulatory aspects of the mid- and late-stage pipeline. So we will aim at keeping any commercial or finance questions for another day. We want science and patience to take center stage.
During the call, we’ll highlight the most important events in 2025 across our pipeline in immunology, rare diseases, hemato-oncology, neurology and vaccines and provide the key news flow items for the first half and the second half of next year and 2027. Because a couple of 2025 news items deflated expectations, we believe that next year’s news flow comes with lower anticipation in general. The presentation will
Read the full article here
